Ken Griffin Inventiva S.A. Call Options Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IVA
# of Institutions
12Shares Held
4.93MCall Options Held
0Put Options Held
0-
Yiheng Capital Management, L.P. San Francisco, CA2.64MShares$9.71 Million0.81% of portfolio
-
Nea Management Company, LLC Timonium, MD1.46MShares$5.37 Million0.39% of portfolio
-
Bvf Inc San Francisco, CA686KShares$2.52 Million0.09% of portfolio
-
Commonwealth Equity Services, LLC54.3KShares$199,3430.0% of portfolio
-
Ubs Group Ag27.4KShares$100,7340.0% of portfolio
About Inventiva S.A.
- Ticker IVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,134,200
- Market Cap $155M
- Description
- Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company als...